389 related articles for article (PubMed ID: 28967916)
1. Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease.
Cruz NM; Song X; Czerniecki SM; Gulieva RE; Churchill AJ; Kim YK; Winston K; Tran LM; Diaz MA; Fu H; Finn LS; Pei Y; Himmelfarb J; Freedman BS
Nat Mater; 2017 Nov; 16(11):1112-1119. PubMed ID: 28967916
[TBL] [Abstract][Full Text] [Related]
2. Genetics of cystogenesis in base-edited human organoids reveal therapeutic strategies for polycystic kidney disease.
Vishy CE; Thomas C; Vincent T; Crawford DK; Goddeeris MM; Freedman BS
Cell Stem Cell; 2024 Apr; 31(4):537-553.e5. PubMed ID: 38579684
[TBL] [Abstract][Full Text] [Related]
3. Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease.
Li SR; Gulieva RE; Helms L; Cruz NM; Vincent T; Fu H; Himmelfarb J; Freedman BS
Nat Commun; 2022 Dec; 13(1):7918. PubMed ID: 36564419
[TBL] [Abstract][Full Text] [Related]
4. Mouse models of polycystic kidney disease induced by defects of ciliary proteins.
Ko JY; Park JH
BMB Rep; 2013 Feb; 46(2):73-9. PubMed ID: 23433108
[TBL] [Abstract][Full Text] [Related]
5. Acute kidney injury induces hallmarks of polycystic kidney disease.
Kurbegovic A; Trudel M
Am J Physiol Renal Physiol; 2016 Oct; 311(4):F740-F751. PubMed ID: 27488998
[TBL] [Abstract][Full Text] [Related]
6. Polycystin-1 transforms the cAMP growth-responsive phenotype of M-1 cells.
Sutters M; Yamaguchi T; Maser RL; Magenheimer BS; St John PL; Abrahamson DR; Grantham JJ; Calvet JP
Kidney Int; 2001 Aug; 60(2):484-94. PubMed ID: 11473631
[TBL] [Abstract][Full Text] [Related]
7. Prothymosin α promotes STAT3 acetylation to induce cystogenesis in Pkd1-deficient mice.
Chen YC; Su YC; Shieh GS; Su BH; Su WC; Huang PH; Jiang ST; Shiau AL; Wu CL
FASEB J; 2019 Nov; 33(11):13051-13061. PubMed ID: 31589480
[TBL] [Abstract][Full Text] [Related]
8. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].
Covic M; Covic M
Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):11-20. PubMed ID: 18677899
[TBL] [Abstract][Full Text] [Related]
10. Drug discovery for polycystic kidney disease.
Sun Y; Zhou H; Yang BX
Acta Pharmacol Sin; 2011 Jun; 32(6):805-16. PubMed ID: 21642949
[TBL] [Abstract][Full Text] [Related]
11. Pannexin-1 mediates fluid shear stress-sensitive purinergic signaling and cyst growth in polycystic kidney disease.
Verschuren EHJ; Rigalli JP; Castenmiller C; Rohrbach MU; Bindels RJM; Peters DJM; Arjona FJ; Hoenderop JGJ
FASEB J; 2020 May; 34(5):6382-6398. PubMed ID: 32159259
[TBL] [Abstract][Full Text] [Related]
12. Progressive development of polycystic kidney disease in the mouse model expressing Pkd1 extracellular domain.
Kurbegovic A; Trudel M
Hum Mol Genet; 2013 Jun; 22(12):2361-75. PubMed ID: 23439951
[TBL] [Abstract][Full Text] [Related]
13. A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.
Kakade VR; Tao S; Rajagopal M; Zhou X; Li X; Yu AS; Calvet JP; Pandey P; Rao R
J Mol Cell Biol; 2016 Dec; 8(6):464-476. PubMed ID: 27190311
[TBL] [Abstract][Full Text] [Related]
14. Myocardin-Related Transcription Factor Mediates Epithelial Fibrogenesis in Polycystic Kidney Disease.
Lichner Z; Ding M; Khare T; Dan Q; Benitez R; Praszner M; Song X; Saleeb R; Hinz B; Pei Y; Szászi K; Kapus A
Cells; 2024 Jun; 13(11):. PubMed ID: 38891116
[TBL] [Abstract][Full Text] [Related]
15. Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo.
Liu M; Zhang C; Gong X; Zhang T; Lian MM; Chew EGY; Cardilla A; Suzuki K; Wang H; Yuan Y; Li Y; Naik MY; Wang Y; Zhou B; Soon WZ; Aizawa E; Li P; Low JH; Tandiono M; Montagud E; Moya-Rull D; Rodriguez Esteban C; Luque Y; Fang M; Khor CC; Montserrat N; Campistol JM; Izpisua Belmonte JC; Foo JN; Xia Y
Cell Stem Cell; 2024 Jan; 31(1):52-70.e8. PubMed ID: 38181751
[TBL] [Abstract][Full Text] [Related]
16. In vitro cystogenesis: the search for drugs antagonizing cyst development.
Ibraghimov-Beskrovnaya O; Bukanov NO
Nephrol Ther; 2006 Jan; 2 Suppl 2():S109-14. PubMed ID: 17373209
[TBL] [Abstract][Full Text] [Related]
17. Cystic gene dosage influences kidney lesions after nephron reduction.
Le Corre S; Viau A; Burtin M; El-Karoui K; Cnops Y; Terryn S; Debaix H; Bérissi S; Gubler MC; Devuyst O; Terzi F
Nephron; 2015; 129(1):42-51. PubMed ID: 25531116
[TBL] [Abstract][Full Text] [Related]
18. Kidney: polycystic kidney disease.
Paul BM; Vanden Heuvel GB
Wiley Interdiscip Rev Dev Biol; 2014; 3(6):465-87. PubMed ID: 25186187
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic advances in the treatment of polycystic kidney disease.
Riella C; Czarnecki PG; Steinman TI
Nephron Clin Pract; 2014; 128(3-4):297-302. PubMed ID: 25573484
[TBL] [Abstract][Full Text] [Related]
20. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.
Shillingford JM; Murcia NS; Larson CH; Low SH; Hedgepeth R; Brown N; Flask CA; Novick AC; Goldfarb DA; Kramer-Zucker A; Walz G; Piontek KB; Germino GG; Weimbs T
Proc Natl Acad Sci U S A; 2006 Apr; 103(14):5466-71. PubMed ID: 16567633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
